SEARCH

SEARCH BY CITATION

References

  • Amara S. G. & Sonders M. S. (1998) Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51, 8796.DOI: 10.1016/s0376-8716(98)00068-4
  • Barker E. L., Moore K. R., Rakhshan F., Blakely R. D. (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19, 47054717.
  • Bennett J. P. Jr (1978) Methods in binding studies, in Neurotransmitter Receptor Binding ( YamamuraH. I., EnnaS. J. and KuharM. J., eds), pp. 5790. Raven Press, New York.
  • Bennett E. R., Su H., Kanner B. I. (2000) Mutation of arginine-44 of GAT-1, a (Na++ Cl)-coupled GABA transporter from rat brain, impairs net flux but not exchange. J. Biol. Chem. 275, 3410634113.
  • Chen N. & Justice J. B. J. (1998) Cocaine acts as an apparent competitive inhibitor at the outward-facing conformation of the human norepinephrine transporter: kinetic analysis of inward and outward transport [in process citation]. J. Neurosci. 18, 1025710268.
  • Chen N. & Justice J. B. (2000) Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine. Brain Res. Mol. 75, 208215.
  • Chen N. & Reith M. E. A. (2000) Structure and function of the dopamine transporter. Eur J. Pharmacol. 405, 329339.
  • Chen N., Ferrer J. V., Javitch J. A., Justice J. B. Jr (2000) Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter. J. Biol. Chem. 275, 16081614.
  • Cheng Y. & Prusoff W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 30993108.
  • Daniels G. M. & Amara S. G. (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274, 3579435801.
  • Dougherty D. A. (1996) Cation–pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 271, 163168.
  • Ferrer J. V. & Javitch J. A. (1998) Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc. Natl Acad. Sci. USA 95, 92389243.
  • Fersht A. (1985). Enzyme Structure and Mechanism, pp. 98120. W.H. Freeman, New York.
  • Galli A., Blakely R. D., DeFelice L. J. (1998) Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake [see comments]. Proc. Natl Acad. Sci. USA 95, 1326013265.
  • Gallivan J. P. & Dougherty D. A. (1999) Cation–π interactions in structural biology. Proc. Natl Acad. Sci. USA 96, 94599464.
  • Giros B., Jaber M., Jones S. R., Wightman R. M., Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606612.
  • Keshet G. I., Bendahan A., Su H., Mager S., Lester H. A., Kanner B. I. (1995) Glutamate-101 is critical for the function of the sodium and chloride-coupled GABA transporter GAT-1. FEBS Lett. 371, 3942.DOI: 10.1016/0014-5793(95)00859-8
  • Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M., Uhl G. R. (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA 89, 77827785.
  • Lanyi J. K. (1997) Mechanism of ion transport across membranes. Bacteriorhodopsin as a prototype for proton pumps. J. Biol. Chem. 272, 3120931212.
  • Lee F. J., Pristupa Z. B., Ciliax B. J., Levey A. I., Niznik H. B. (1996) The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. J. Biol. Chem. 271, 2088520894.
  • Lin Z., Wang W., Kopajtic T., Revay R. S., Uhl G. R. (1999) Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56, 434447.
  • Lin Z., Wang W., Uhl G. R. (2000) Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains. Mol. Pharmacol. 58, 15811592.
  • Martin S., Botto J. M., Vincent J. P., Mazella J. (1999) Pivotal role of an aspartate residue in sodium sensitivity and coupling to G proteins of neurotensin receptors. Mol. Pharmacol. 55, 210215.
  • Masson J., Sagné C., Hamon M., El Mestikawy S. (1999) Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51, 439464.
  • Melikian H. E., Ramamoorthy S., Tate C. G., Blakely R. D. (1996) Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol. Pharmacol. 50, 266276.
  • Nguyen T. T. & Amara S. G. (1996) N-Linked oligosaccharides are required for cell surface expression of the norepinephrine transporter but do not influence substrate or inhibitor recognition. J. Neurochem. 67, 645655.
  • Opdenakker G., Rudd P. M., Ponting C. P., Dwek R. A. (1993) Concepts and principles of glycobiology. FASEB J. 7, 13301337.
  • Poolman B., Knol J., Van Der Does C., Henderson P. J., Liang W. J., Leblanc G., Pourcher T., Mus-Veteau I. (1996) Cation and sugar selectivity determinants in a novel family of transport proteins. Mol. Microbiol. 19, 911922.
  • Rees S., Coote J., Stables J., Goodson S., Harris S., Lee M. G. (1996) Bicistronic vector for the creation of stable mammaliam cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20, 102110.
  • Reith M. E. A. (2000) From first to fourth messengers in the brain: an overview, in Cerebral Signal Transduction ( ReithM. E. A., ed.), pp. 323. Humana Press, Totowa, NJ.
  • Reith M. E., Xu C., Zhang L., Coffey L. L. (1996) Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn Schmiedebergs Arch. Pharmacol. 354, 295304.
  • Rudnick G. (1997) Mechanisms of biogenic amine neurotransmitter transporters, in: Neurotransmitter Transporters: Structure, Function, and Regulation ( ReithM. E. A., ed.), pp. 73100. Humana Press, Totowa, NJ.
  • Schömig E., Körber M., Bönisch H. (1988) Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn Schmiedebergs Arch. Pharmacol. 337, 626632.
  • Stein M. D. (1986). Transport and Diffusion Across Cell Membranes, pp. 231361. Academic Press,Orlando, FL.
  • Steiner-Mordoch S., Shirvan A., Schuldiner S. (1996) Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate. J. Biol. Chem. 271, 1304813054.
  • Sugamori K. S., Lee F. J., Pristupa Z. B., Niznik H. B. (1999) A cognate dopamine transporter-like activity endogenously expressed in a COS-7 kidney-derived cell line. FEBS Lett. 451, 169174.DOI: 10.1016/s0014-5793(99)00557-8
  • Vaughan R. A. (1995) Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol. Pharmacol. 47, 956964.
  • Vaughan R. A. (2000) Regulation of dopamine transporter by phosphorylation and impact on cocaine action, in: Cerebral Signal Transduction ( ReithM. E. A., ed.), pp. 375400. Humana Press, Totowa, NJ.
  • Vaughan R. A. & Kuhar M. J. (1996) Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis. J. Biol. Chem. 271, 2167221680.
  • Xu C. & Reith M. E. (1997) WIN 35,428 and mazindol are mutually exclusive in binding to the cloned human dopamine transporter. J. Pharmacol. Exp. Ther. 282, 920927.
  • Zimányi I., Lajtha A., Reith M. E. A. (1989) Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn Schmiedebergs Arch. Pharmacol. 340, 626632.